Ramp­ing back up on on­col­o­gy, GSK takes an op­tion on Adap­ti­m­mune’s TCR can­cer drug

New GSK CEO Em­ma Walm­s­ley is go­ing for it in on­col­o­gy.

Look­ing to steer the phar­ma gi­ant back to­ward a pipeline that can stir some re­al ex­cite­ment among in­vestors, the GSK chief has de­cid­ed to pick up an ex­clu­sive op­tion on Adap­ti­m­mune’s NY-ESO SPEAR T-cell ther­a­py pro­gram.

Adap­ti­m­mune $ADAP is in line now for $61 mil­lion dur­ing the tran­si­tion pe­ri­od — part for the op­tion and part in mile­stones. GSK gets full rights cov­er­ing the de­vel­op­ment and hoped for com­mer­cial­iza­tion of the TCR ther­a­peu­tic, a tech cousin to the CAR-Ts now mak­ing their de­but.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.